Myomo, Inc. announced the resignation of Steve Sanghi from its Board of Directors to focus on his duties as CEO and Board Chairman of Microchip Technology Inc. He will continue to serve as an a advisor to Myomo and remain a personal investor in the company. Lead Independent Director, Thomas F. Kirk, will replace Mr. Sanghi on Myomo’s Audit Committee.
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patientâs own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individualâs ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteranâs administration, and others.
MYOMO, INC. 
